SOURCE: Active Biotech

February 12, 2009 11:37 ET

ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA

JERUSALEM and LUND, SWEDEN--(Marketwire - February 12, 2009) - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. Food and Drug Administration (FDA). Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod (ALLEGRO) in November 2008 and is currently enrolling RRMS patients globally for the second Phase III study (BRAVO).

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • Contact:
    Elana Holzman
    Teva Pharmaceutical Industries Ltd.
    +972-(3)-926-7554

    Kevin Mannix
    Teva North America
    +1-(215)-591-8912

    Contact:
    Tomas Leanderson
    Active Biotech AB
    +46-46-19-20-95

    Göran Forsberg
    Active Biotech AB
    +46-46-19-11-54